Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the

① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.

cls.cnMar 2 21:09 ET

AI helps reduce costs and improve efficiency in drug development. The "AI+Medical" Industry has explosive growth opportunities.

China Post Securities pointed out that the Global market size for AI+Medical industry AI solutions is expected to increase from 13.7 billion dollars in 2022 to 155.3 billion dollars in 2030, with a CAGR of 35.5%, indicating explosive growth opportunities in the industry.

cls.cnFeb 27 19:05 ET

BeiGene, Ltd. (ONC) Q4 2024 Earnings Call Transcript Summary

moomoo AIFeb 27 10:29 ET · Conference Call

The wave of AI in Medical is sweeping: the potential of the macromolecule new drug market is highlighted and imaging products are "going overseas" into Emerging Markets | Focus

① Some executives from pharmaceutical companies have stated that "currently, the discovery of small molecule drugs is very challenging; finding potential molecules and structures is already quite difficult, while there is still significant potential in the discovery and design of large molecule new drugs." ② Currently, the application maturity of AI technology in the imaging field is relatively high, and relevant manufacturers have revealed that the market potential for AI imaging large models in Belt and Road Initiative Concept countries is quite extensive.

cls.cnFeb 26 20:37 ET

JiangSu WuZhong Pharmaceutical Development is suspected of violations related to information disclosure and has been filed for investigation after years of losses, just turning a profit.|Brief Announcement

① JiangSu WuZhong Pharmaceutical Development has been put under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws; ② The company has reported a net income loss for six consecutive years, yet aims to turn a profit in 2024 by focusing on a single product in the medical aesthetics sector; ③ Previously, the company faced several instances of being penalized for various legal violations, but none have occurred in the last three years.

cls.cnFeb 26 09:00 ET

The final judgment resulted in a compensation exceeding 60 million yuan, Tonghua Dongbao Pharmaceutical revised its performance forecast | Interpretations

① The final judgment requires compensation to Gan & Lee Pharmaceuticals exceeding 60 million yuan, and Tonghua Dongbao Pharmaceutical adjusts its performance for 2024; ② The company's controlling shareholder Dongbao Group has pledged shares amounting to nearly 30% of the company's total equity.

cls.cnFeb 26 07:46 ET